The global clinical trial equipment & ancillary solutions market size was valued at USD 2.7 billion in 2022 and is anticipated to exhibit a compound annual growth rate (CAGR) of 8.1% from 2023 to 2030. The global market has noticed critical growth on account of the rising R&D investments, evolving need for clinical trials, and the rapid growth of the pharmaceutical and medical industries. The COVID-19 outbreak temporarily slowed down the process of clinical trials in 2020, owing to the national lockdown implemented by the government, which had affected the market negatively. However, the growing demand for an effective treatment for COVID-19 and other diseases improves the number of trials post covid. For instance, according to ClinicalTrial.Gov, 325,761 studies were reported in 2020, whereas in 2022 the number of studies reached 399502 by 2023. The surge in clinical studies is expected to support the market post-pandemic.
As clinical trials evolve, more resources are required for a clinical trial, including the drugs, equipment, and ancillary supplies. Ancillary supplies include all items necessary to perform a clinical study, such as syringes, surgical knives, swabs, gloves, and any other material that the patient and medical professional need to administer the medication and analyze the effectiveness and safety parameters under examination.
Sourcing equipment & ancillary materials for clinical trials involves considerably more than just procurement. It needs an in-depth understanding of the study’s design and requirements, as well as rigorous proactive planning to guarantee that the most relevant equipment and supplies are bought at the correct time and at a reasonable price. A combination of internal knowledge and external help is strongly recommended in handling the complexity of equipment and ancillary supply, restocking, logistics, and expiry management.
There is a massive rise in the number of clinical studies being undertaken for COVID-19, and this is expected to improve market growth. Apart from this high investment in R&D and adoption of virtual clinical trials owing to the pandemic have further supported the market growth.
The supply/logistics segment dominated the market and accounted for the largest revenue share of 38.8% in 2022. As clinical trials have become more global and diverse, they require a proper cold chain logistics system to maintain the integrity of temperature-sensitive drugs. Fluctuation in rules & regulations in emerging markets is expected to boost the need for supply/logistic services during the forecast period.
The sourcing segment on the other hand is anticipated to witness a considerable growth rate of 7.9% across the forecast period. Due to the increasing complexity of clinical trials, the quantity of equipment and ancillary supplies required, as well as the number of diverse suppliers required to supply them, has increased substantially. The challenge of ensuring that supplies reach sites in a cost-effective manner for worldwide research has increased. With sourcing and distribution expertise, there is a single point of contact to supply and transport equipment and ancillary supplies all over the world. This streamlined and coordinated procedure removes the strain on both clinical trial teams and facilities.
The phase III segment accounted for the maximum revenue share of the global market of 54.1% in 2022. The segment is likely to remain dominant even during the forecast years. Clinical studies in phase III are more complicated than those in earlier stages. Even though the number of medicines in this phase is relatively minimal, the complications associated with this phase are the largest.
In addition, the failure rate is also highest in this phase as the sample size and research design need precise dosing at an optimal level. The failure causes both human and financial damage, and most failures are caused by non-compliance with safety requirements. Such a scenario is likely to increase the demand for effective supply chain and logistics, which is projected to boost market growth over the coming years.
The phase I segment is poised to witness significant growth across the forecast period due to the increasing number of pharmaceutical companies focusing on developing novel therapeutics for rare diseases. Growth in the number of CROs across the world is another factor supporting the adoption of phase I clinical trials to boost the rapid development of drugs.
North America dominated the global clinical trial equipment & ancillary solutions market in 2022 with the largest revenue share of 40.4%. This is attributed to the fact that most pharmaceutical businesses are located in the U.S. and perform most of their business in this region. Favorable regulatory policies, the introduction of technologically advanced products by the market players, and increasing investments by pharmaceutical firms are expected to drive regional market growth during the forecast period.
Asia Pacific is projected to be the fastest-growing regional market with a CAGR of 9.5% during the forecast period. The Asia Pacific region has become a hotspot for conducting clinical trials on account of the ease of regulatory compliance, cheap study costs, a growing patient population, and the existence of a few elite clinical institutions functioning as sites.
Mergers, acquisitions, expansions, and collaborations, are the key strategies adopted by key players to maintain their market share. For instance, in September 2021, Ancillare acquired NG BV in the Netherlands. The acquisition strengthens Ancillare's supply chain capabilities in the pharmaceutical products area, offering sponsors worldwide greater control and supply chain transparency. In July 2021, Parexel announced an inventive collaboration with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to design patient-centric protocol designs and methodologies for decentralized clinical trials in China. This will also involve quantitative research to enhance the clinical trial experience of oncology patients. Some prominent players in the global clinical trial equipment & ancillary solutions market are:
Ancillare, LP
Imperial CRS
Woodley Equipment Company Ltd.
Thermo Fisher Scientific, Inc.
PAREXEL International Corp.
Emsere (Medicapital Rent)
Quipment SAS
IRM
Marken A UPS Company
Myonex
Yourway
Report Attribute |
Details |
Market size value in 2023 |
USD 3.0 billion |
Revenue forecast in 2030 |
USD 5.10 billion |
Growth rate |
CAGR of 8.1% from 2023 to 2030 |
Base year for estimation |
2022 |
Actual estimates/Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
May 2023 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments Covered |
Product, phase, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; Colombia; South Africa, Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Ancillare LP; Imperial CRS; Woodley Equipment Company Ltd.; Thermo Fisher Scientific, Inc.; PAREXEL International Corp.; Emsere (Medicapital Rent); Quipment SAS; IRM; Marken A UPS Company; Myonex; Yourway |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global clinical trial equipment & ancillary solutions market based on product, phase, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Sourcing
Procurement
Equipment
Ancillaries
Rental
Equipment
Ancillaries
Supply/Logistics
Transportation
Packaging
Others
Service
Calibrations
Equipment Servicing
Others
Others
Phase Outlook (Revenue, USD Million, 2018 - 2030)
Phase I
Phase II
Phase III
Phase IV
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global clinical trial equipment & ancillary solutions market size was estimated at USD 2.7 billion in 2022 and is expected to reach USD 3.0 billion in 2023.
b. The global clinical trial equipment & ancillary solutions market is expected to grow at a compound annual growth rate of 8.1% from 2023 to 2030 to reach USD 5.1 billion by 2030.
b. North America dominated the clinical trial equipment & ancillary solutions market with a share of 40.4% in 2022. This is attributable to the huge R&D investments, the presence of global players, and their efforts to come up with newer patents.
b. Some key players operating in the clinical trial equipment & ancillary solutions market include Ancillare LP, Imperial Clinical Research Services, Woodley Equipment Company LTD, Thermo Fisher Scientific Inc., PPD Inc.
b. Key factors that are driving the clinical trial equipment & ancillary solutions market growth include rising R&D investments, the evolving need for clinical trials, and the increase in the growth of pharmaceutical and medical industries.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."